Published in PLoS One on May 01, 2012
Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. PLoS One (2015) 1.39
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Replication characteristics of swine influenza viruses in precision-cut lung slices reflect the virulence properties of the viruses. Vet Res (2013) 0.82
Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One (2013) 0.78
Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines. J Virol (2014) 0.76
Mutations during the Adaptation of H9N2 Avian Influenza Virus to the Respiratory Epithelium of Pigs Enhance Sialic Acid Binding Activity and Virulence in Mice. J Virol (2017) 0.75
Emerging role of Natural killer cells in oncolytic virotherapy. Immunotargets Ther (2015) 0.75
Fighting Cancer with Mathematics and Viruses. Viruses (2017) 0.75
Targeting Melanoma with Cancer-Killing Viruses. Open Virol J (2017) 0.75
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol (2006) 6.22
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul (2006) 3.32
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 2.65
Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J Virol (2007) 2.44
Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol (1998) 2.42
Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J (2003) 2.38
Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res (2010) 2.33
NS1 protein of influenza A virus down-regulates apoptosis. J Virol (2002) 2.12
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol (2004) 1.84
Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells. Cell Microbiol (2006) 1.77
Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg (2005) 1.66
A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol (2009) 1.50
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther (2011) 1.45
Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol (2004) 1.41
Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein. Proc Natl Acad Sci U S A (2010) 1.34
Avian influenza virus A/HK/483/97(H5N1) NS1 protein induces apoptosis in human airway epithelial cells. J Virol (2008) 1.27
Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res (2004) 1.21
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Human influenza A viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells. Virology (2003) 1.05
Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int J Cancer (2003) 1.04
A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res (2001) 1.04
Loss of function of the influenza A virus NS1 protein promotes apoptosis but this is not due to a failure to activate phosphatidylinositol 3-kinase (PI3K). Virology (2009) 1.03
Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. Int J Cancer (2004) 0.98
Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther (2011) 0.97
Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res (2011) 0.97
Infection of human retinal pigment epithelial cells with influenza A viruses. Invest Ophthalmol Vis Sci (2009) 0.94
NK sensitivity of neuroblastoma cells determined by a highly sensitive coupled luminescent method. Biochem Biophys Res Commun (2005) 0.92
The non-structural (NS1) protein of influenza A virus associates with p53 and inhibits p53-mediated transcriptional activity and apoptosis. Biochem Biophys Res Commun (2010) 0.90
Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. J Virol (2006) 0.88
The NS1 protein of influenza A virus interacts with heat shock protein Hsp90 in human alveolar basal epithelial cells: implication for virus-induced apoptosis. Virol J (2011) 0.87
Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells. Med Microbiol Immunol (2009) 0.86
Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency. J Virol (2010) 0.85
AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice. Blood (2011) 0.84
Endogenous expression of proteases in colon cancer cells facilitate influenza A viruses mediated oncolysis. Cancer Biol Ther (2010) 0.81
Immunotherapy for metastatic melanoma. J Cell Biochem (2012) 0.81
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One (2008) 6.98
Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol (2003) 4.66
Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci (2002) 2.32
Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain. Clin Chem (2006) 2.32
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst (2009) 2.09
Osteoarthritis - an untreatable disease? Nat Rev Drug Discov (2005) 1.93
Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol (2005) 1.78
Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs. Virology (2003) 1.70
Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol (2009) 1.65
Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol (2002) 1.63
Novel swine-origin influenza A virus in humans: another pandemic knocking at the door. Med Microbiol Immunol (2009) 1.60
Phylogeny of the SARS coronavirus. Science (2003) 1.56
Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev (2002) 1.54
Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release (2003) 1.54
The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia (2009) 1.49
Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology (2004) 1.45
Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol (2004) 1.44
Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra. J Clin Microbiol (2002) 1.42
Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol (2004) 1.41
Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence. Trends Microbiol (2003) 1.39
Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev (2005) 1.38
The clinical value of neutrophil extracellular traps. Med Microbiol Immunol (2009) 1.34
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med (2006) 1.34
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res (2009) 1.34
Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc Natl Acad Sci U S A (2005) 1.33
Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur J Immunol (2010) 1.31
Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci (2004) 1.24
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett (2007) 1.20
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis (2010) 1.18
Burst discharge in primary sensory neurons: triggered by subthreshold oscillations, maintained by depolarizing afterpotentials. J Neurosci (2002) 1.17
N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol (2009) 1.16
Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS One (2011) 1.14
Severe acute respiratory syndrome: identification of the etiological agent. Trends Mol Med (2003) 1.13
Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer (2003) 1.12
Valproic acid as anti-cancer drug. Curr Pharm Des (2007) 1.11
Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J Antimicrob Chemother (2007) 1.11
Molecular mechanisms of the modulatory effects of HCMV infection in tumor cell biology. Trends Mol Med (2004) 1.11
Susceptibility to chronic pain following nerve injury is genetically affected by CACNG2. Genome Res (2010) 1.10
Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students. Med Microbiol Immunol (2007) 1.10
Comparison of pro-inflammatory cytokine expression and cellular signal transduction in human macrophages infected with different influenza A viruses. Med Microbiol Immunol (2010) 1.09
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol (2009) 1.09
Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol (2011) 1.08
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol (2005) 1.08
Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol (2005) 1.08
SARS molecular detection external quality assurance. Emerg Infect Dis (2004) 1.08
The threat of avian influenza A (H5N1). Part IV: Development of vaccines. Med Microbiol Immunol (2007) 1.06
Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS One (2011) 1.06
Determination of risk of infection with blood-borne pathogens following a needlestick injury in hospital workers. Ann Occup Hyg (2008) 1.05
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis (2002) 1.05
Neutrophils and the blood-brain barrier dysfunction after trauma. Med Res Rev (2007) 1.04
Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One (2009) 1.04
Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol (2004) 1.03
Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed? Med Microbiol Immunol (2009) 1.03
First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion (2009) 1.02
Inhibition of apoptosis prevents West Nile virus induced cell death. BMC Microbiol (2007) 1.02
Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol (2005) 1.02
Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res (2004) 1.01
Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun (2005) 1.01
Nitrate and the GATA factor AreA are necessary for in vivo binding of NirA, the pathway-specific transcriptional activator of Aspergillus nidulans. Mol Microbiol (2002) 1.01
Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res (2003) 0.99
Increased plasma kynurenine values and kynurenine-tryptophan ratios after major trauma are early indicators for the development of sepsis. Shock (2009) 0.98
Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev Mol Diagn (2007) 0.98
Antiviral activity of caspase inhibitors: effect on picornaviral 2A proteinase. FEBS Lett (2004) 0.97
Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol (2004) 0.97
Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol (2006) 0.97
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia (2010) 0.97